In our cohort, a marked improvement was observed in the DFS survival rates for the patients with ‘weak/negligible cytoplasmic’ EBP50-expressing tumours, while the survival rate of patients with ‘predominantly cytoplasmic’ EBP50 steadily declined over time. This evidence concerns the gene NHERF1 and neoplasm.